Summary of kidney cancer highlights from ASCO GU 2024
This year’s American Society of Clinical Oncology Genitourinary Cancers (ASCO [...]
ASCO 2021: Nivolumab plus ipilimumab for the treatment of kidney cancer brain metastases
Brain metastases resulting from the spread of renal cell carcinoma [...]
ASCO 2021: Baseline characteristics affect survival with nivolumab plus cabozantinib
Ongoing results from the phase 3 CheckMate-9ER clinical trial with [...]
ASCO 2021: Nivolumab plus cabozanitinib for non-clear cell kidney cancer
The cabozantinib/nivolumab combination has been shown to be effective at [...]
ASCO 2021: Telaglenastat plus cabozantinib for metastatic kidney cancer
Cell metabolism in renal cell carcinoma (RCC) tumours is disrupted, [...]
ASCO 2021: Health-related quality of life for lenvatinib plus pembrolizumab for advanced kidney cancer
Results from the phase 3 CLEAR study were presented at [...]
ASCO 2021: Cobozantinib plus nivolumab combination for non-clear cell kidney cancer
The cabozantinib/nivolumab combination has been shown to be effective at [...]
ASCO 2021: Pembrolizumab as adjuvant therapy for kidney cancer
Adjuvant therapy is medication that is given in addition to [...]
ASCO GU 2021: Outcomes of first-line immunotherapy combinations in metastatic kidney cancer
Combinations of immunotherapy drugs nivolumab plus ipilimumab and immunotherapy/vascular endothelial [...]
ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer
Results from the phase 3 CLEAR study, presented at the [...]
